

Abstract:

The present invention relates to the production of a population of virus-specific CTLs in which the population contains an anti-virus specific gene expression construct. This population can be combined with a population of CD4+ T lymphocytes or a population of CD34+ hematopoietic progenitor cells and one or more of these populations of cells can be delivered to an autologous virus-positive individual. The present invention also relates to therapeutic cell products and to methods of treating diseases, particularly infectious diseases.